TAT-Gap19 acetate 是 connexin43 hemichannel (Cx43 HC) 的特异性抑制剂。 它穿过血脑屏障并减轻小鼠的肝纤维化。它不抑制相应的 Cx43 GJC。

TAT-Gap19 acetate is a specific inhibitor of connexin43 hemichannel (Cx43 HC). TAT-Gap19 acetate traverses the blood-brain barrier and alleviates liver fibrosis in mice. TAT-Gap19 acetate does not inhibit the corresponding Cx43 GJCs.

TAT-Gap19 acetate (1 mg/kg/day) showed significantly decreased collagen deposition, as well as lower amounts of α-SMA-positive cells area in mice subjected to treatment with 100-200 mg thioacetamide (TAA)/kg body weight for eight weeks[1]. In 4 months old C57Bl6 male mice, TAT-Gap19 acetate (i.v.; 55 mg/kg) produces significant immune signal in the brain 24 h later[2].

TP2110L

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years